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Inflammatory Breast Cancer (IBC) is the most aggressive
and highly metastatic form of breast cancer [1-3]. In a
recent study [4], we analysed breast cancer with peritu-
moral neoplastic lymphovascular invasion (ePVI) in com-
parison with inflammatory breast cancer, showing that
ePVI breast cancer have more clinicopathologic affinity
than differences with the most aggressive cancer in the
breast. Here, we aim to identify potential master regulators
(MRs) that drive the expression pattern in IBC.
Transcriptomic (i.e., mRNA) data from 197 breast
tumours were used for this analysis (GEO GSE23720) [5].
All tumours were classified as “IBC” (n=63) or “nIBC”
(n=134). To identify novel MRs that drive the IBC
phenotype, all expression data were analysed using a
network-based strategy (ARACNe [6]) and Master
Regulator Analysis (MRA)[7]. We chose to perform in-
vivo IHC analysis, in two independent cohorts of IBCs
(n = 39), nIBCs (n = 82) and normal breast tissues
(n = 15), for the top significant Master Regulators: MGA,
CTNNB1 and NFAT5. Biological validation confirmed
that NFAT5 expression was higher in IBC than in nIBC
(70% vs. 20%) and that the majority of NFAT5-positive
IBC samples displayed NFAT5 nuclear expression in com-
parison with nIBC samples (89% vs. 12%).
We provide evidence that NFAT5 transcription factor
could constitute a novel IBC biomarker that could help
to identify the most aggressive forms of BC into routine
clinical practice.
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